ALKS

Alkermes PLC

Price

$50.18

return (12m)

73.93%

p/e

124.40

p/bv

4.55

DIVIDEND YIELD

0.00%

ALKS price

Alkermes

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALKS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-3.85%

3 months

35.81%

1 year

73.93%

2 years

77.75%

5 years

79.63%

10 years

19.03%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ALKS

Valuation

P/E

124.40

Sector -4.38

Industry -4.38

P/BV

4.55

Sector 2.02

Industry 2.02

P/Revenue (PSR)

4.93

Sector -4.40

Industry -4.40

EV/EBITDA

166.49

Sector -263.09

Industry -263.09

EV/EBIT

376.12

Sector -702.90

Industry -702.90

P/EBITDA

37.72

Sector -4.39

Industry -4.39

P/EBIT

52.59

Sector -4.73

Industry -4.73

P/Total Assets

1.87

Sector 1.49

Industry 1.49

P/Net Current Assets

-7.75

Sector -11.70

Industry -11.70

P/Working Capital

9.56

Sector -3.19

Industry -3.19

EPS

0.40

Sector -2.14

Industry -2.14

BVPS

10.83

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

84.56%

Sector 36.74%

Industry 36.74%

EBITDA Margin

10.95%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

4.85%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

8.62%

Sector -38.22%

Industry -38.22%

Net Profit Margins

3.96%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.11

Sector 0.03

Industry 0.03

Profitability

ROE

3.66%

Sector -65.14%

Industry -65.14%

ROA

1.51%

Sector -65.53%

Industry -65.53%

ROIC

0.00%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

2.30

Sector 2.90

Industry 2.90

Net Debt / EBITDA

15.09

Sector -6.07

Industry -6.07

Net Debt / EBIT

34.10

Sector -8.26

Industry -8.26

Net Debt / Equity

0.45

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.82

Sector -0.05

Industry -0.05

Equity/Assets

0.41

Sector 0.41

Industry 0.41

Liabilities/Assets

0.59

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

7.28%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Alkermes ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$50.18

Fair Value

$9.87

Upside Return potential.

-80.33%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ALKS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ALKS Alkermes PLC	$50.18	73.93%	0.00%	124.40	4.55	3.66%	3.96%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALKS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Alkermes

Alkermes PLC

Average Investor10 user rating

4.0 (2 people)

United States

15 years

Founded: 2011

1991

Time since IPO - 35 years

2.245

Employees

Alkermes PLC (United States) is listed on the Nasdaq and has a market capitalization of $8.23 billion, with shareholders equity totaling $1.81 billion.

The company employs approximately 2.245 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Alkermes PLC reported $1.67 billion in revenue, generating net income of $66.12 million.

Key financial metrics include a P/E ratio of 124.40, a price-to-book (P/B) ratio of 4.55, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALKS.

Market cap

$8.23 billion

Net worth

$1.81 billion

$1,808,550,000.00

Assets

$4.39 billion

$4,393,120,000.00

Total Shares Outstanding

167.00 million

167,000,000

Average Daily Trading Volume

$2.11 million

$2,108,756.00

Sector

Health Care

Industry

Biotechnology

ALKS

ALKS revenue and profits

Financial Results ALKS

DRAG THE FRAME TO SEE MORE DATA

ALKS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Alkermes (ALKS) today?

A cotação de Alkermes (ALKS) hoje está em US$ 50.18, com uma variação de 73.93% em relação ao último ano. A cotação de Alkermes (ALKS) iniciou o ano negociando na casa dos US$ 27.98 e hoje está em US$ 50.18. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Alkermes (ALKS) e dados de ações do Ibovespa e mercados internacionais.

Quando Alkermes (ALKS) paga dividendos?

Alkermes (ALKS) não distribuiu dividendos no último ano.

Is Alkermes (ALKS) a good investment?

Atualmente, Alkermes (ALKS) está cotada a US$ 50.18, com um P/L de 124.40, representando um desvio de 2,879% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 73.93 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 73.93%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Alkermes (ALKS) stock?

Investir em ações de Alkermes (ALKS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Alkermes (ALKS) yield today?

A rentabilidade de Alkermes (ALKS) foi de -3.85% no último mês, 73.93% no último ano e 79.63% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Alkermes (ALKS) hoje, o investimento total seria de US$ 5,018.00, com base na cotação atual de US$ 50.18.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 8,727.81
Em 5 anos: US$ 9,013.83
Em 10 anos: US$ 5,972.93

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ALKS

Alkermes PLC

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ALKS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING ALKS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Alkermes

Alkermes PLC

United States

15 years

1991

2.245

PROFIT X PRICE ALKS

Financial Results ALKS

ALKS cash flow

Asset, Revenue and Profit Growth - ALKS

ALKS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions